Press coverage about Trevena (NASDAQ:TRVN) has trended positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Trevena earned a daily sentiment score of 0.37 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.7555698332811 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several brokerages recently issued reports on TRVN. Oppenheimer reaffirmed a “buy” rating and set a $5.00 target price on shares of Trevena in a research report on Monday, November 13th. Zacks Investment Research lowered Trevena from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a research report on Saturday, January 20th. Needham & Company LLC reduced their target price on Trevena from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Trevena in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $6.94.
Shares of Trevena (NASDAQ:TRVN) traded down $0.01 during trading hours on Friday, reaching $1.68. The company had a trading volume of 341,784 shares, compared to its average volume of 627,892. Trevena has a 12 month low of $1.34 and a 12 month high of $7.16. The firm has a market cap of $104.98, a price-to-earnings ratio of -1.02 and a beta of -0.51. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 0.38.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.